Vasodilator Treatment of Primary Pulmonary Hypertension

  • L. Cotter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 164)


Primary pulmonary hypertension has been defined as pulmonary artery hypertension and normal pulmonary capillary wedge pressure with right ventricular hypertrophy for which no aetiology is apparent (1). The clinical diagnosis is made by excluding other causes of pulmonary hypertension, although differentiation from chronic pulmonary thromboembolic disease may be impossible ante-mortem. It predominantly affects young women causing their death after median period of 2 – 3 years (2) although long term follow up (3) and even spontaneous remission (4) have been reported in exceptional cases. Although its cause is unknown the pathological changes include medical hypertrophy and laminar intimai arteriolar fibrosis suggesting a vasoconstrictive element in the genesis of the disease (5). Some cases are familial (6) and as autoimmune disease is present in about the third of cases (7), immunological mechanisms have been suggested in the genesis of the disease. A disease indistinguishable from primary pulmonary hypertension occurred in patients in central Europe who took the weight reducing agent aminorex fumarate (8), and 4 others taking the antidiabetic agent phenformin (9,10).


Pulmonary Hypertension Pulmonary Artery Pressure Pulmonary Vascular Resistance Pulmonary Blood Flow Primary Pulmonary Hypertension 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    S. Hatano, T. Strasser, Primary pulmonary hypertension report on a WHO meeting. World Health Organization. (1975).Google Scholar
  2. 2.
    R.P. Gatewood, P.N. Yu, Primary pulmonary hypertension. Prog. Card. (1979).Google Scholar
  3. 3.
    L. Suarez, Long-term follow-up in primary pulmonary hypertension. Br. Heart J. 41: 702 (1979).PubMedCrossRefGoogle Scholar
  4. 4.
    P.D.V. Bourdillon, C.M. Oakley, Regression of primary pulmonary hypertension. Br. Heart J. 38: 264 (1976).PubMedCrossRefGoogle Scholar
  5. 5.
    P. Wood, Pulmonary hypertension with special reference to the vasoconstrictive factor. Br. Heart J. 21: 557 (1959).Google Scholar
  6. 6.
    R.C. Clarke, C.F. Coombs, G. Hadfield, A.T. Todd, On certain abnormalities congenital and aquired of the pulmonary arteries. Q. J. Med. 21: 51 (1927).CrossRefGoogle Scholar
  7. 7.
    C.A. Wangevoort, N. Wangevoort, Pathology of pulmonary hypertension. New York, John Willey and Sons, (1977).Google Scholar
  8. 8.
    J.M. Kay, P. Smith, D. Heath, Aminorex and the pulmonary circulation. Thorax 26: 262 (1971).PubMedCrossRefGoogle Scholar
  9. 9.
    M. Fahlen, H. Bergman, Phenformin and pulmonary hypertension. Br. Heart J. 35: 82 (1973).CrossRefGoogle Scholar
  10. 10.
    B.J. Sproule, E.A. Phillipson, C.M. Couves, R.T. Brownlee, Acute pulmonary hypertension in idiopathic lactic acidosis. Canadian Medical Association Journal 94: 141 (1966).PubMedGoogle Scholar
  11. 11.
    M. Honey, L. Cotter, N. Davies, D. Denison, Clinical and haemodynamic effects of diazoxide in primary pulmonary hypertension. Thorax 35: 269 (1980).PubMedCrossRefGoogle Scholar
  12. 12.
    J. Koch-Weser, Drug therapy: diazoxide. N. Engl. J. Med. 294: 1271 (1976).PubMedCrossRefGoogle Scholar
  13. 13.
    M. Moser, Diazoxide: an effective vasodilator in accelerated hypertension. Am. Heart J. 87: 791 (1974).PubMedCrossRefGoogle Scholar
  14. 14.
    N.J.H. Davies, D.M. Denison, The measurement of metabolic gas exchange by mass spectrometry alone. Respir. Physiol. 36: 261 (1979).PubMedCrossRefGoogle Scholar
  15. 15.
    D.T. Dresdale, M. Schultz, R.J. Michton, Primary pulmonary hypertension. Am. J. Med. 11: 686 (1951).PubMedCrossRefGoogle Scholar
  16. 16.
    R.F. Grover, J. Reeves, S.G. Blount, Tolazoline hydrochloride: an effective pulmonary vasodilator. Am. Heart J. 61:5 (1961).PubMedCrossRefGoogle Scholar
  17. 17.
    U. Shettigar, H.N. Hultgren, M. Speatr, R. Martin, H.D. Davies, Primary pulmonary hypertension: favorable effect of isoproterenol. N. Engl. J. Med. 295: 1414 (1976).PubMedCrossRefGoogle Scholar
  18. 18.
    D.E.L. Wilckin, K.M. MacKenzie, J.F. Goodwin, Anticoagulation therapy of obliterative pulmonary hypertension. Lancet 1: 781 (1960).CrossRefGoogle Scholar
  19. 19.
    F. Rengo, B. Trimarco, M. Chiarello, Histamine and hypoxic pulmonary hypertension: a quantitative study. Cardiovasc. Res. 12: 752 (1978).PubMedCrossRefGoogle Scholar
  20. 20.
    J. Szczeklik, Effects of prostaglandin El on the pulmonary circulation in patients with pulmonary hypertension. Br. Heart J. 40: 1397 (1978).PubMedCrossRefGoogle Scholar
  21. 21.
    F.S. Daoud, J.T. Reeves, D.B. Kelly, Isoproterenol as a potential pulmonary vasodilator in primary pulmonary hypertension. Am. J. Cardiol. 42: 817 (1978).PubMedCrossRefGoogle Scholar
  22. 22.
    J.N. Ruskin, A.M. Hutter, Primary pulmonary hypertension treated with phentolamine. Ann. Intern. Med. 90: 772 (1979).PubMedGoogle Scholar
  23. 23.
    U. Elkayam, W. Frishman, C. Yoran, J. Strom, M. Cohen, Unfavourable haemodynamic and clinical effects of isoproterenol therapy in primary pulmonary hypertension. Card. Med. 3: 1177 (1978).Google Scholar
  24. 24.
    R.J. Rubin, H.R. Peter, Oral Hydrallazine therapy for primary pulmonary hypertension. N. Engl. J. Med. 302: 69 (1980).PubMedCrossRefGoogle Scholar
  25. 25.
    F. Camerini, E. Alberti, S. Klugman, A. Salvi, Primary pulmonary hypertension: effects of Nifedipine. Br. Heart J. 44: 352 (1980).PubMedCrossRefGoogle Scholar
  26. 26.
    S.W.S. Wang, J.E.F. Pohl, D.J. Rowlands, E.G. Wade, Diazoxide in treatment of primary pulmonary hypertension. Br. Heart J. 40: 572 (1978).PubMedCrossRefGoogle Scholar
  27. 27.
    W.P. Klinke, J.A.L. Gilbert, Diazoxide in primary pulmonary hypertension. N. Engl. J. Med. 302: 91 (1980).PubMedCrossRefGoogle Scholar
  28. 28.
    J.E.F. Pohl, B. Thurstan, Use of diazoxide in hypertension with renal failure. Br. Med. J. 1: 142 (1971).CrossRefGoogle Scholar
  29. 29.
    S. Rich, Vasodilator therapy for pulmonary hypertension (letter) N. Engl. J. Med. 302: 1260 (1980).PubMedCrossRefGoogle Scholar
  30. 30.
    J.T. Reeves, Hope in primary pulmonary hypertension. N. Engl. J. Med. 302: 81 (1980).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • L. Cotter
    • 1
  1. 1.Brompton HospitalLondonEngland

Personalised recommendations